Vincristine sulfate liposomal injection for acute lymphoblastic leukemia

Trisha A Soosay Raj,1 Amanda M Smith,2 Andrew S Moore,1,21Royal Children's Hospital, Children's Health Queensland Hospital and Health Service, Brisbane, Queensland, Australia; 2Queensland Children's Medical Research Institute, The University of Queensland, Brisbane, QLD, Aust...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Soosay Raj TA, Smith AM, Moore AS
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/d32dd0b169144dda9a57652f7329c9f5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d32dd0b169144dda9a57652f7329c9f5
record_format	dspace
spelling	oai:doaj.org-article:d32dd0b169144dda9a57652f7329c9f52021-12-02T08:08:31ZVincristine sulfate liposomal injection for acute lymphoblastic leukemia1176-91141178-2013https://doaj.org/article/d32dd0b169144dda9a57652f7329c9f52013-11-01T00:00:00Zhttp://www.dovepress.com/vincristine-sulfate-liposomal-injection-for-acute-lymphoblastic-leukem-a14900https://doaj.org/toc/1176-9114https://doaj.org/toc/1178-2013Trisha A Soosay Raj,1 Amanda M Smith,2 Andrew S Moore,1,21Royal Children's Hospital, Children's Health Queensland Hospital and Health Service, Brisbane, Queensland, Australia; 2Queensland Children's Medical Research Institute, The University of Queensland, Brisbane, QLD, AustraliaAbstract: Vincristine (VCR) is one of the most extensively used cytotoxic compounds in hemato-oncology. VCR is particularly important for the treatment of acute lymphoblastic leukemia (ALL), a disease that accounts for approximately one-third of all childhood cancer diagnoses. VCR's full therapeutic potential has been limited by dose-limiting neurotoxicity, classically resulting in autonomic and peripheral sensory–motor neuropathy. In the last decade, however, the discovery that liposomal encapsulation of chemotherapeutics can modulate the pharmacokinetic characteristics of a compound has stimulated much interest in liposomal VCR (vincristine sulfate liposomal injection [VSLI]) formulations for the treatment of ALL and other hematological malignancies. Promising data from recent clinical trials investigating VSLI in adults with ALL resulted in US Food and Drug Administration approval for use in patients with Philadelphia chromosome (t[9;22]/BCR–ABL1) (Ph)-negative (Ph-) disease. Additional clinical trials of VSLI in adults and children with both Ph-positive (Ph+) and Ph- ALL are ongoing. Here we review the preclinical and clinical experience to date with VSLI for ALL.Keywords: vincristine sulfate liposomal injection, liposomes, sphingosomal vincristine, acute lymphoblastic leukemia, chemotherapySoosay Raj TASmith AMMoore ASDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2013, Iss Issue 1, Pp 4361-4369 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Soosay Raj TA Smith AM Moore AS Vincristine sulfate liposomal injection for acute lymphoblastic leukemia
description	Trisha A Soosay Raj,1 Amanda M Smith,2 Andrew S Moore,1,21Royal Children's Hospital, Children's Health Queensland Hospital and Health Service, Brisbane, Queensland, Australia; 2Queensland Children's Medical Research Institute, The University of Queensland, Brisbane, QLD, AustraliaAbstract: Vincristine (VCR) is one of the most extensively used cytotoxic compounds in hemato-oncology. VCR is particularly important for the treatment of acute lymphoblastic leukemia (ALL), a disease that accounts for approximately one-third of all childhood cancer diagnoses. VCR's full therapeutic potential has been limited by dose-limiting neurotoxicity, classically resulting in autonomic and peripheral sensory–motor neuropathy. In the last decade, however, the discovery that liposomal encapsulation of chemotherapeutics can modulate the pharmacokinetic characteristics of a compound has stimulated much interest in liposomal VCR (vincristine sulfate liposomal injection [VSLI]) formulations for the treatment of ALL and other hematological malignancies. Promising data from recent clinical trials investigating VSLI in adults with ALL resulted in US Food and Drug Administration approval for use in patients with Philadelphia chromosome (t[9;22]/BCR–ABL1) (Ph)-negative (Ph-) disease. Additional clinical trials of VSLI in adults and children with both Ph-positive (Ph+) and Ph- ALL are ongoing. Here we review the preclinical and clinical experience to date with VSLI for ALL.Keywords: vincristine sulfate liposomal injection, liposomes, sphingosomal vincristine, acute lymphoblastic leukemia, chemotherapy
format	article
author	Soosay Raj TA Smith AM Moore AS
author_facet	Soosay Raj TA Smith AM Moore AS
author_sort	Soosay Raj TA
title	Vincristine sulfate liposomal injection for acute lymphoblastic leukemia
title_short	Vincristine sulfate liposomal injection for acute lymphoblastic leukemia
title_full	Vincristine sulfate liposomal injection for acute lymphoblastic leukemia
title_fullStr	Vincristine sulfate liposomal injection for acute lymphoblastic leukemia
title_full_unstemmed	Vincristine sulfate liposomal injection for acute lymphoblastic leukemia
title_sort	vincristine sulfate liposomal injection for acute lymphoblastic leukemia
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/d32dd0b169144dda9a57652f7329c9f5
work_keys_str_mv	AT soosayrajta vincristinesulfateliposomalinjectionforacutelymphoblasticleukemia AT smitham vincristinesulfateliposomalinjectionforacutelymphoblasticleukemia AT mooreas vincristinesulfateliposomalinjectionforacutelymphoblasticleukemia
_version_	1718398628031102976

Vincristine sulfate liposomal injection for acute lymphoblastic leukemia

Ejemplares similares